BIOCYTOGEN-B (02315) saw its share price jump by more than 7% during intraday trading, before paring gains to trade 3.06% higher at HK$57.25, with a trading volume of HK$80.6283 million.
The company announced that it expects to achieve revenue of between RMB 936 million and RMB 946 million for the first half of 2026, representing a year-on-year increase of 50.80% to 52.41%. The net profit attributable to parent company is projected to be between RMB 236 million and RMB 246 million, a surge of 392% to 413% compared to the same period last year.
The significant performance improvement is primarily attributed to the company's forward-looking research and development strategy and a high-quality client network. Both of its major business lines have achieved dual-engine growth, driving rapid revenue expansion. Additionally, the company has realized economies of scale, deepened lean management, and improved its gross profit margin. This has led to a reduction in the period expense ratio, significantly enhancing profitability.
As of December 31, 2025, BIOCYTOGEN-B had signed over 350 drug collaboration, licensing, or transfer agreements. Its sub-brand, Bio-Med, has established thousands of gene-edited animal and cell models, holds a globally leading library of target humanized mice, and provides global clients with full-chain support services, including preclinical pharmacology and efficacy studies, gene editing services, and model construction.
Comments